The redox-active chlorite-based drug WF10 (Immunokine) was shown to have modulatory effects on both the innate and adaptive immune system in vitro and in vivo. Animal studies suggest that WF10 enhances immunity against tumors. One possible explanation for such an effect is that WF10 stimulates natural killer cell cytotoxicity against malignant cells. Here, we show that WF10 regulates human NK cell cytotoxicity in a time-dependent manner, following an S-shaped kinetic with an initial stimulation of activity followed by a decrease in activity relative to the untreated controls. WF10 does not activate NK cells on its own but costimulates NK cell activation mediated by different activating receptors. This is mediated by enhancing NK cell adhesion to target cells through promoting the activation of the integrin LFA-1. These data demonstrate a direct effect of WF10 on the cytotoxicity of human NK cells.
Introduction
Natural killer (NK) cells are important effector cells for innate immune reactions against viral infections and malignant cells [1] . NK cell effector functions include cellular cytotoxicity and the secretion of cytokines and chemokines. They also fulfill a regulatory role by engaging in cross-talk with diverse cellular components of the immune system [2] . NK cell cytotoxicity is regulated through the recognition of target cells by integrating positive and negative signals from activating and inhibitory receptor-ligand interactions [3] . Many inhibitory NK cell receptors are specific for self-MHC class I and are important to ensure the self-tolerance of NK cells. Loss of MHC class I upon viral infection or malignant transformation can, therefore, result in the socalled "missing-self " reactivity of NK cells. NK cell activation is mediated by a variety of different surface receptors that can recognize specific ligands on transformed or infected cells. Interestingly, freshly isolated resting human NK cells can only be activated by triggering two or more activating receptors in combination [4] . Therefore, all stimulatory receptors for natural cytotoxicity are considered to be coactivating. The only exception seems to be CD16, which is sufficient by itself to induce activation of resting NK cells.
NK cell adhesion to target cells is essential for enabling the interaction between NK cell receptors and their ligands within the immunological synapse and for the directed release of granules towards the attached target cell during NK cell cytotoxicity [5] . NK cell adhesion is mediated by integrins such as LFA-1. The function of LFA-1 is regulated by "inside-out signaling", where signals from other surface receptors influences the affinity of LFA-1 by inducing conformational changes of the molecule, and also affects the avidity of LFA-1 by driving mobility within the cell membrane [6] . This results in clustering of LFA-1 at the site of the NK cell synapse. Adhesion is, therefore, a highly regulated and dynamic process necessary for the function of NK cells. [7] [8] [9] . WF10 is known to have various immunological effects by stimulating innate immune functions, while inhibiting adaptive immune functions [10] . In contrast to control animals, sublethally irradiated rats treated with WF10 developed significantly less hematological or solid tumors than controls [11, 12] . This antitumor effect of WF10 could be explained by stimulating the innate natural cytotoxicity against tumors. We, therefore, investigate the effect of WF10 on NK cell cytotoxicity.
Materials and Methods

Materials and Cells
. WF10/Immunokine (containing ca. 63 μM chlorite) was provided by Dimethaid GmbH, Wanzleben, Germany. The following antibodies were used: MOPC21 (IgG1 isotype control, Sigma), antiNKp30 (p30-15, generated in our lab), antiNKp46 and antiCD16 (Beckmann Coulter), anti2B4 (Immunotech), antiNKG2D and antiDNAM-1 (R&D Systems). Human ICAM-1-Fc was from R&D Systems, PE-conjugated goat-antihuman Fcγ fragment-specific IgG F(ab )2 fragment from Jackson Immuno Research. K562, LCL721.221 and P815 cells were maintained as described [13, 14] . Human NK cells were isolated from PBMC by negative selection (Dynal, Invitrogen) and cultured as described [15] .
Cytotoxicity Assay.
For 51 Cr release assays, target cells were labeled with 100 μCi of 51 Cr for 1 h at 37
• C. The labeled cells were washed, mixed with NK cells at different effectorto-target (E : T) ratios on a 96-well V-bottom plate and incubated for 4 h at 37
• C. For redirected lysis assay NK cells were preincubated with antibodies (0.5 μg/ml final concentration) for 15 min at 37
• C before adding the target cells. The supernatant was harvested and 51 Cr-release was measured in a γ-counter. Percent specific release was calculated as ((experimental release-spontaneous release)/(maximum releasespontaneous release)) × 100. The ratio between maximum and spontaneous release was at least three in all experiments.
2.3.
Real-Time PCR Analysis. NK cells were incubated with or without WF10 for 3 or 18 h. At the end of the incubation cells were lysed in 300 μl MagNA pure lysis buffer containing 1% DTT and mRNA was isolated using the MagnaPure-LC device. Isolated mRNA was transcribed into cDNA using AMV reverse transcriptase (First Strand cDNA synthesis kit (Roche)). Indicated primer sets (Search-LC, Heidelberg) were used with LightCycler-FastStart DNS Sybr Green I Kit (Roche) to amplify the cDNA using the LightCycler according to the manufacture's protocol. The number of transcripts of specific genes in each sample was normalised using the number of transcripts of the house-keeping genes β-actin and cyclophilin b. The transcript number was calculated from a virtual standard curve, obtained by plotting a known input concentration of a plasmid to the PCR cycle number (CP) at which the detected fluorescence intensity reaches a fixed value. For better visualization, a log 2 transformation, of the ratio between WF10-treated and control samples was calculated, as is common for gene expression studies [10] .
Conjugate Formation Assay and Ligand Complex-Based Adhesion Assay (LC-AA).
NK cell-target cell conjugate formation was measured by flow cytometry as described previously [13] . Briefly, freshly isolated NK cells were labeled with the dye PKH67 and LCL721.221 target cells with PKH26 (Sigma). Target and NK cells were combined and incubated with or without WF10 (final concentration of 200 μM chlorite) at 37 • C. Reactions were stopped by vortexing, cells were fixed with ice-cold 4% PFA and number of conjugates were determined by FACS analysis. The ligand-complexbased adhesion assay (LC-AA) assesses the activation of the adhesion molecule LFA-1 by FACS analysis of cell bound fluorescently-labeled ICAM-1-complexes and was performed as published [16, 17] . For statistical analysis SPSS Statistics 17.0 was used. 
Results and Discussion
WF10 Can Increase the Cytotoxic Activity of Human NK
Cells. To test whether WF10 is able to boost the cytotoxic activity of NK cells, we used freshly isolated human NK cells in a standard 4 h 51 Cr-release assay against the MHC class I-negative B cell line LCL721.221. At a therapeutic concentration of 200 μM active chlorite content WF10 significantly enhanced the cytotoxic activity of NK cells (Figures 1(a) and  1(b) ). This effect was also seen when PBMC (data not shown) and IL-2-activated human NK cells were used (Figures 1(c)  and 1(d) ). The enhancement of the NK cell cytotoxicity by WF10 was dose-dependent and could also be observed when NK cells were pretreated with WF10 before the assay (Figure 2(a) ). However, WF10 did not directly affect the viability of target cells and pretreatment of target cells with WF10 did not alter their susceptibility to NK-mediated lysis (Figure 2(b) ). These data demonstrate that WF10 specifically enhances the cytotoxic activity of NK cells. This effect was not restricted to 721.221 target cells, but also the lysis of the leukemic cell line K562 and the pancreatic cancer cell line Miapaca were enhanced by WF10 (data not shown).
Time-Dependent Effect of WF10.
The increase in NK cell cytotoxicity by WF10 was time-dependent, following an Sshaped kinetic over 24 hours (Figure 3) . After an initial boost of activity, WF10 inhibited NK cell cytotoxicity after 18 h of pretreatment (Figures 3(b) and 3(c) ). Preincubation of NK cells for 24 hours did no longer result in differences of cytotoxicity between WF10 or control treated cells. The inhibition of NK cell cytotoxicity was not due to a cytotoxic effect of WF10 as we only detected a minor increase in NK cell apoptosis after 18 h of WF10-treatment. However, consistent with previous findings that WF10 affects gene transcription by modulating certain transcription factors in PBMC [10] , we detected a reduced expression of cytotoxicity-related genes such as NKG2D, Perforin and DAP12 by quantitative RT-PCR after 18 h of WF10-treatment (Figure 4 ), which might explain the reduction in cytotoxicity.
WF10 Enhances NK Cell Cytotoxicity Mediated by Different Activating Receptors.
Next we wanted to test if the WF10-mediated enhancement of NK cell activity was mediated through a specific activating receptor. Therefore, we triggered NK cell cytotoxicity through NKp30, NKG2D or 2B4 in a redirected lysis assay. In line with the concept of NK cell coactivation [4] , triggering of any of these receptors on freshly isolated NK cells did not stimulate cytotoxicity. Also the addition of WF10 did not change this. However, when we used IL-2-activated NK cells, WF10 could enhance NK cell cytotoxicity mediated by CD16, NKG2D, NKp30 and 2B4 ( Figure 5 ). This suggests that WF10 acts independently of one specific receptor proximal signaling pathway. Interestingly, WF10 can only costimulate NK cell cytotoxicity but does not lead to NK cell activation on its own.
WF10 Enhances Target Cell Adhesion and Co-Stimulates
the Activation of LFA-1. As WF10 acted independently of specific receptor signaling pathways, we tested its effect on NK cell adhesion to target cells. This adhesion is essential for NK cell cytotoxicity. It allows the interaction of NK cell receptors with their ligands on the target cells and is essential for the directed release of cytotoxic granules. During the first 90 minutes of conjugate formation between freshly isolated NK cells and 721.221 target cells WF10 showed only a minor effect. However, at later time points WF10-treatment resulted in an increase in the amount of conjugates (Figure 6(a) ). LFA-1 is an important adhesion molecule on NK cells. The affinity and avidity of LFA-1 for its ligand ICAM-1 is regulated by inside-out-signals that can derive from cytokines or the activation of cytotoxicity receptors [6] . We, therefore, tested the binding activity of LFA-1 using a ligand-complex-based adhesion assay (LC-AA) [16] . In this assay fluorescently-labeled ICAM-1 complexes are used for the staining of cells in a FACS-based analysis. These adhesion to target cells by costimulating inside-out signaling resulting in higher LFA-1 activity. This would explain the higher cytotoxic activity of NK cells after WF10-treatment and suggests that rather than hyperactivating a few NK cells to kill more frequently, WF10 may increase the number of NK cells involved in cytotoxicity at a given time, so that cells that were previously insufficiently activated are now recruited to the killing process by WF10. This would be in line with our finding that WF10 can costimulate NK cells, but not activate them on its own.
Concluding Remarks
WF10 was shown to inhibit the development and promotion of leukemia in animal models [11, 12] . The role of oxidative species in cancer is complex and has been extensively studied in the last decades. ROS appear to have a dual role in tumor development and growth. Oxidative species contribute to DNA damage, a major step in carcinogenesis and progression, but they can also act in pro-apoptotic signaling pathways and, therefore, have antitumor effects [18] . Due to this dual role, some anticancer strategies are based on pro-oxidant mechanisms and some on antioxidant mechanisms [19] . In addition to these direct effects, we have shown in this study that WF10 can stimulate NK cell cytotoxicity through promoting LFA-1-mediated adhesion to tumor cells. As NK cells are known to be important effector cells against hematological malignancies [20] , it may be promising to combine WF10 with other strategies of NK cellbased immunotherapy against cancer. However, the effects of WF10 on immune function appears to be modulatory, rather than either stimulatory or inhibitory. It is, therefore, expected that a treatment with WF10 could only temporary enhance NK cell functions, followed by a phase of reduced NK cell activity. It is unclear if this transient inhibition of NK cell cytotoxicity, possibly mediated by the downregulation of cytotoxicity-related genes such as NKG2D, DAP12, or perforin, would lead to a gap in immune defense mechanisms. However, this transient inhibition of NK cell cytotoxicity may be overcome by combining the WF10-based therapy with stimulatory substances, such as Interleukin-15, for which a synergistic effect in combination with WF10 has been shown in our study. Additionally, our data would suggest that it may be beneficial to administer WF10 in individual boosts rather than maintaining a constant drug level in order to exploit its influence on NK cell activity.
